Today is October 18th 2018. That is exactly two years since my dear wife became an angel and exactly one year since the incorporation of MCS Foundation for Life with the aim of helping advanced cancer patients to live a better and longer life.
I promised I am going to share with you some very exciting news regarding a new treatment approach that based on early and anecdotal reports, in my view, represents one of the most promising approaches to treat cancer.
I will use this special day to release these news:
Lampidis Cancer Foundation, USA (website), together with MCS Foundation for Life, the Netherlands (website), are actively preparing to collaborate with clinics worldwide on implementing protocols using 2-DG for patients who have failed standard treatment. This is a massive step towards making 2-DG accessible to cancer patients worldwide.
The details of this project have been made available at the website of Lampidis Cancer Foundation here.
Essentially, this new project relates to a new method to deliver 2DG to cancer patients, in a metronomic manner, meant to improve or enable effectiveness of conventional therapies including but not limited to chemo- and radio-therapies.
2DG has been previously discussed on this website (Ref.) and has been already given to cancer patients both in the context of clinical trials performed years ago in USA, and in private clinics around the world including in German clinics. But the results were not as exciting as expected.
Today, based on the research findings of Prof. Lampidis, professor of cell biology at the Miller School of Medicine in Miami, we now understand that when 2DG was given to the patients in the past trials, because 2DG “looks” like glucose, there is a subsequent release of insulin in the human body, redirecting 2-DG to fat and muscle and away from the tumor site. As a result, when given all at once, 2-DG cannot reach the tumor tissue at the relevant amount and for a long enough time-frame required to have a negative impact on cancer cells, similar to that observed in laboratory. That is not what we want.
A new approach to get 2-DG into the tumors
In order to avoid the insulin release and get the 2DG to the tumor, Prof. Lampidis came up with a trick. Instead of giving the 2DG all at once as it is being given typically to patients around the world, Dr. Lampidis proposed to give that in a much lower dose and during long time, up to a few days, at a rate and concentration that is below the insulin-inducing dose. That is what we call metronomic delivery of 2-DG.
It is not a question but a certainty that 2DG will reach the tumor at a very low dose. Why? Because 2DG is the very same substance that is used in the solution given to the patients prior to PET-CT scan. In that scan, 2DG is connected to a radioactive substance. Because 2DG looks like glucose, and because we know very well by now that tumors like glucose, 2DG will be absorbed by the tumors while the radioactive substance will behave like the blinking light sending the signal outside the human body and indicating the location of 2DG. That is how PET-CT works. And so from PET-CT scans we know that the absorption of 2DG at low dose is very selective and mainly absorbed by the tumors.
Using the strength of 2-DG to help conventional therapies work
Once getting the 2DG to the tumor, this will put pressure on the tumor via various mechanisms, including the reduction of energy (ATP) production which is required by the multi drug resistance (MDR) pumps to push chemotherapy out of cancer cells and including the reduction of anti-oxidant production required by cancer cells to fight the pro-oxidant nature of chemo- and radio-therapy. Prof. Lampidis has identified other mechanisms that may be even more relevant than these two and will be further discussed as soon as I get further clarity on that line.
Now imagine that we can use such an approach to put pressure on cancer cells, and lower their capability to fight conventional therapies. Imagine that we can use this while or just after the conventional therapies are given to the patient. Imagine how more effective the conventional therapy may become. And that would be nearly independent on the cancer type since most of the tumors are relying on glucose for the short term need of resources. Actually, we do not even need to imagine how much the conventional therapy can be improved. Instead, read this post I wrote some years ago, when a substance working in a “similar” fashion could be used in a hospital in US to make advanced cancer patients respond again to conventional therapies. Actually, the dose of conventional therapies could even be reduced when supported by a substance “similar” to 2-DG.
Next to the very clear and extensive scientific evidence supporting 2-DG, the prior results mentioned at this post is what made me very enthusiast when I head about the findings of Prof. Lampidis on metronomic 2-DG. The great advantage of 2-DG is that is a substance already used in humans, in clinical trials and in PET-CT. It’s safety profile is relatively well known and with limited or no toxicity. It is accessible as it is produced at compounding Pharmacy in Germany ready for intravenous administration. And it’s cheap. Perfect combination of attributes: effective, safe at known doses, accessible & cheap.
The implementation of this new approach to help enable and/or increase effectiveness of conventional therapies, is beeing done in 3 different steps:
- Implementation on a compassionate basis, by clinicians located in countries and institutions where this is allowed
- Here, Lampidis Cancer Foundation & MCS Foundation for Life, informs the patients and clinicians, and supports clinicians with the implementation
- Implementation via limited number of clinics around the world that can receive the approval to do so in a structural manner (such as being done by DaySpringClinic in USA with other substances)
- Here, Lampidis Cancer Foundation & MCS Foundation for Life, supports a few selected clinics with the documentation required for application for approval at the relevant boards
- Implementation of 2-DG as a widely available drug, which will require FDA approval and clinical trials before that
At this point, there is a treatment protocol in place that is shared by Lampidis Cancer Foundation & MCS Foundation for Life on compassionate basis with clinicians around the world, addressing point #1 above. At the same time, the two foundations and collaborators, are working on point #2 and #3 above.
Patients interested in learning more about this approach can contact us and will be glad to inform.
Medical doctors interested in learning more and implementing this approach can contact us and will be glad to inform and continue supporting with our knowledge during the implementation process.
Very encouraging anecdotal reports
Although the data is still at an anecdotal stage, it is encouraging to know that multiple patients across the world are reporting excellent tolerance with metronomic 2-DG treatment, when used immediately after chemotherapy.
While these patients are being co-treated with other agents as well, they all seem to experience positive outcome following the treatment approach that includes metronomic 2-DG, from just feeling better to reduction in the size of their respective tumor types and markers.
All of the patients are advanced cancer patients with no or limited treatment options. While we do not have the consensus to publish their data yet, I can at least shortly and anecdotally mention several cases:
- Endometrial cancer
- see case report from Marcos https://www.cancertreatmentsresearch.com/good-news-from-marcos/
- Colon cancer
- 70+ women; colon cancer & liver metastasis; 18% marker reduction after one week treatment
- Brain cancer
- women; brain cancer progressing while on TMZ; feeling better since implementing metronomic 2DG https://www.cancertreatmentsresearch.com/good-news-from-marcos/#comment-7732
- Pancreatic cancer
- 70+ man; pancreatic cancer with liver metastasis; tumor markers exploding during the summer; Gemcitabine only stopped the growth of markers; implemented metronomic 2DG and several other treatments. 90% decline of tumor markers in the following two months (family of patient will create own website to share experience – I will share the link as soon as that is available)
- 30 yeas old lady; sarcoma with metastasis; combining IPT (low dose chemo) with 2DG metronomic and a few other treatments and reporting feeling better, and feeling regression of some palpable tumors
- Ovarian cancer
- 50+ women; ovarian tumor with mets at liver, spline, ascites fast evolving; started two months of IPT (low dose chemo) & metronomic 2-DG and a few other treatments; two months after no tumor visible on MRI and patient feeling well
So far, the results we hear back are along the line of our expectation, and I am veryy happy to be able to say that. It’s important to say that the reports from nearly 100% of the patinets I know using it are indicating improvements.
The international team behind the metronomic 2-DG project
Dr. Metin Kurtoglu holds an MD and Ph.D. in cell biology and is one of the world’s leading experts in the mechanisms by which 2-DG works as well as its clinical application. Dr. Metin Kurtoglu and Dr. Theodore J. Lampidis have worked closely together and have published extensively on 2-DG as an anti-cancer agent. Dr. Kurtoglu, based in Washington DC, is also developing a novel CAR T immunotherapy that is currently in Phase I clinical trials.
Dr. Daniel Stanciu, based in the Netherlands, holds a Ph.D. in physics and has become an expert in traditional as well as new cancer treatments since his beloved wife Mihaela, who recently passed away, was diagnosed with cancer in 2013. Daniel is now devoting his life and career to helping others suffering from this devastating disease, through the MCS Foundation for Life. He has attracted a following of more than one million views to his blog, where he presents scientific information consolidated around new or improved approaches to treat advanced cancer.
Dr. Theodore J. Lampidis, Ph.D. is a professor of cell biology at the Miller School of Medicine in Miami, trained at the Dana Farber Cancer Institute, Harvard Medical School, and whose lab is internationally known for its work on developing 2-DG as a universal treatment for numerous cancer types. Dr. Lampidis is a leading authority on exploiting cancer glucose metabolism with sugar analogs.
The role of the two Foundations:
Lampidis Cancer Foundation, USA (website), based on the extensive knowledge acquired from prior research and prior clinical trials on 2DG, is in the lead for the following:
- establishing and sharing the metronomic treatment protocol with medical doctors interested
- supports clinicians during the implementation process, when required
- translates report results into potential next steps including documentation required for the required steps in clinical trials
- publication of results in scientific papers, and communication with the academic and medical communities to enable next steps
Therefore, main focus and experience of Lampidis Cancer Foundation is around the implementation of metronomic 2DG.
MCS Foundation for Life, the Netherlands (website), based on the extensive knowledge acquired from prior research and application on cancer treatments, as well as constant contact with patients and clinicians across the world, is in the lead for the following:
- contributes to the establishment and adaptation of the metronomic treatment protocol
- informs and maintains contact with patient and medical communities
- supports patients and their doctors with the integration of the metronomic protocol as part of larger treatment strategies
- collects and consolidates reports on results, to inform communities and to be further translated into documentation
Therefore, main focus and experience of MCS Foundation for Life is around the integration of metronomic 2DG.
Another activity that is currently the focus of both of the foundations is finding ways to fund the next steps of this project, with the goal of helping as many patients as possible across the world.
All activities described here are going with the disclaimers presented on this website and at Lampidis Cancer Foundation http://lampidisfoundation.org/2-dg-cancer-treatment-begins-human-trials/
The results of this work that we saw so far and will further experience, are not only due to the team and foundations mentioned above but also and more importantly due to the professional attitude of many people involved including medical doctors, patients and their families.
I would also like to thank you (the reader) in advance for sharing this post on social media platforms such as Facebook & Twiter, to create awareness. You may save a life with that.
Donnations to support the progress and acceleration of this project can be done on this website (with the note “support 2DG project”) or at Lampidis Cancer Foundation (website).
This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.
Please read an extended version of the Disclaimer here: https://www.cancertreatmentsresearch.com/?page_id=1794